State-Regulated Psychedelics on a Collision Course With FDA
JAMA · 26.12.2023 · 330 (24) · 2337
DOI: 10.1001/jama.2023.24762 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 26.12.2023. Verfasst von Mason Marks. Beteiligte Einrichtung: Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Ca…. Hauptthemen laut MEDLINE: Hallucinogens, State Government, United States Food and Drug Administration. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint examines how US states are reforming legislation to allow access to psychedelics for therapeutic use, but federal laws consider these agents to be Schedule I drugs, and the discordance between state and federal law may create confusion and conflict.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, Massachusetts.
- Florida State University College of Law, Tallahassee.
Zitieren
APA
Marks, M. (2023). State-Regulated Psychedelics on a Collision Course With FDA. JAMA, 330(24), 2337. https://doi.org/10.1001/jama.2023.24762
Vancouver
Marks M. State-Regulated Psychedelics on a Collision Course With FDA. JAMA. 2023;330(24):2337. doi:10.1001/jama.2023.24762
BibTeX
@article{Marks2023,
author = {Marks, Mason},
title = {State-Regulated Psychedelics on a Collision Course With FDA},
journal = {JAMA},
year = {2023},
volume = {330},
number = {24},
pages = {2337},
doi = {10.1001/jama.2023.24762}
}
EUVIMED